KBC Group NV Decreases Position in Masimo Co. (NASDAQ:MASI)

KBC Group NV lessened its position in Masimo Co. (NASDAQ:MASIFree Report) by 72.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 3,090 shares of the medical equipment provider’s stock after selling 8,263 shares during the period. KBC Group NV’s holdings in Masimo were worth $362,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in MASI. State of Michigan Retirement System lifted its position in Masimo by 0.9% in the 4th quarter. State of Michigan Retirement System now owns 10,696 shares of the medical equipment provider’s stock valued at $1,254,000 after acquiring an additional 100 shares in the last quarter. Massmutual Trust Co. FSB ADV lifted its holdings in shares of Masimo by 140.6% during the fourth quarter. Massmutual Trust Co. FSB ADV now owns 243 shares of the medical equipment provider’s stock valued at $28,000 after purchasing an additional 142 shares in the last quarter. Parallel Advisors LLC boosted its position in shares of Masimo by 48.3% during the fourth quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 145 shares during the last quarter. CWM LLC increased its holdings in Masimo by 13.5% in the 4th quarter. CWM LLC now owns 1,318 shares of the medical equipment provider’s stock worth $154,000 after buying an additional 157 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its position in Masimo by 0.9% in the 4th quarter. Treasurer of the State of North Carolina now owns 19,139 shares of the medical equipment provider’s stock worth $2,243,000 after buying an additional 180 shares during the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Insider Activity

In related news, Director Craig B. Reynolds sold 40,000 shares of the company’s stock in a transaction on Friday, April 26th. The shares were sold at an average price of $136.17, for a total value of $5,446,800.00. Following the completion of the transaction, the director now owns 7,406 shares of the company’s stock, valued at approximately $1,008,475.02. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 9.70% of the company’s stock.

Masimo Price Performance

Shares of Masimo stock opened at $125.46 on Monday. The stock has a market cap of $6.66 billion, a P/E ratio of 85.35 and a beta of 1.00. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.31 and a current ratio of 2.31. The stock’s fifty day moving average is $131.74 and its 200 day moving average is $125.86. Masimo Co. has a one year low of $75.22 and a one year high of $167.04.

Masimo (NASDAQ:MASIGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The medical equipment provider reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.71 by $0.06. Masimo had a return on equity of 13.26% and a net margin of 4.01%. The company had revenue of $492.80 million during the quarter, compared to the consensus estimate of $487.70 million. During the same period in the previous year, the company posted $0.87 EPS. The firm’s revenue was down 12.8% on a year-over-year basis. Sell-side analysts anticipate that Masimo Co. will post 3.63 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. BTIG Research raised their price target on shares of Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a report on Monday, March 25th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday, May 8th. Stifel Nicolaus raised Masimo from a “hold” rating to a “buy” rating and increased their price target for the company from $148.00 to $170.00 in a report on Monday, April 15th. StockNews.com upgraded Masimo from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Finally, Piper Sandler upgraded Masimo from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $126.00 to $160.00 in a research report on Monday, June 3rd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Masimo has a consensus rating of “Moderate Buy” and an average target price of $143.57.

View Our Latest Research Report on MASI

Masimo Company Profile

(Free Report)

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

Read More

Want to see what other hedge funds are holding MASI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Masimo Co. (NASDAQ:MASIFree Report).

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.